Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Operating Leases (2022 - 2024)

RAPT Therapeutics' Operating Leases history spans 3 years, with the latest figure at $2.6 million for Q3 2024.

  • For Q3 2024, Operating Leases changed N/A year-over-year to $2.6 million; the TTM value through Sep 2024 reached $2.6 million, changed N/A, while the annual FY2023 figure was $4.5 million, 34.62% down from the prior year.
  • Operating Leases for Q3 2024 was $2.6 million at RAPT Therapeutics, down from $3.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.8 million in Q4 2022 and bottomed at $2.6 million in Q3 2024.
  • The 3-year median for Operating Leases is $4.1 million (2023), against an average of $4.5 million.
  • The largest YoY upside for Operating Leases was 34.62% in 2023 against a maximum downside of 34.62% in 2023.
  • A 3-year view of Operating Leases shows it stood at $6.8 million in 2022, then plummeted by 34.62% to $4.5 million in 2023, then crashed by 41.75% to $2.6 million in 2024.
  • Per Business Quant, the three most recent readings for RAPT's Operating Leases are $2.6 million (Q3 2024), $3.2 million (Q2 2024), and $3.8 million (Q1 2024).